Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 6 (1), e000523
eCollection

Relationship Between Baseline Physical Activity Assessed by Pedometer Count and New-Onset Diabetes in the NAVIGATOR Trial

Affiliations

Relationship Between Baseline Physical Activity Assessed by Pedometer Count and New-Onset Diabetes in the NAVIGATOR Trial

William E Kraus et al. BMJ Open Diabetes Res Care.

Abstract

Objective: Physical activity is related to clinical outcomes, even after adjusting for body mass, but is rarely assessed in randomized clinical trials.

Research design and methods: We conducted an observational analysis of data from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial, in which a total of 9306 people from 40 countries with impaired glucose tolerance and either cardiovascular disease or cardiovascular risk factors were randomized to receive nateglinide or placebo, in a 2-by-2 factorial design with valsartan or placebo. All were asked to also participate in a detailed lifestyle modification programme and followed-up for a median of 6.4 years with progression to diabetes as a co-primary end point. Seven-day ambulatory activity was assessed at baseline using research-grade pedometers. We assessed whether the baseline amount of physical activity was related to subsequent development of diabetes in individuals with impaired glucose tolerance.

Results: Pedometer data were obtained on 7118 participants and 35.0% developed diabetes. In an unadjusted analysis each 2000-step increment in the average number of daily steps, up to 10 000, was associated with a 5.5% lower risk of progression to diabetes (HR 0.95, 95%CI 0.92 to 0.97), with >6% relative risk reduction after adjustment.

Conclusions: Physical activity should be measured objectively in pharmacologic trials as it is a significant but underappreciated contributor to diabetes outcomes. It should be a regular part of clinical practice as well.

Keywords: diabetes mellitus; exercise, physical activity; prediabetes.

Conflict of interest statement

Competing interests: TY: Research support from the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre and the NIHR Collaboration for Leadership in Applied Health Research and Care, East Midlands. MAB: Research support from Merck Serono; attended advisory boards with Boehringer Ingelheim, AstraZeneca, and Novo Nordisk. Her department has received research funding from Merck, Amylin, Lilly, and BMS. RRH: Research support from Amylin, Bayer, Merck, and Novartis; attended advisory boards with Amylin, Lilly, Merck, Novartis, and Novo Nordisk; and given lectures supported by Bayer, Lilly, Merck, and Novo Nordisk.

Figures

Figure 1
Figure 1
Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Probabilities of diabetes mellitus (DM) curves were compared using log-rank test (P<0.0001). Individuals at risk at each visit of follow-up were: 9306 (V0), 8230 (V1), 7524 (V2), 7178 (V3), 6582 (V4), 6229 (V5), 5572 (V6), 4876 (V7), 4275 (V8), 2931 (V9), and 510 (V10).

Similar articles

See all similar articles

Cited by 3 PubMed Central articles

References

    1. Surgeon General's report on physical activity and health. From the Centers for Disease Control and Prevention. JAMA 1996;276:522. - PubMed
    1. Physical activity guidelines advisory committee report. Washington DC: US Department of Health and Human Services, 2008.
    1. Leon AS, Connett J. Physical activity and 10.5 year mortality in the Multiple Risk Factor Intervention Trial (MRFIT). Int J Epidemiol 1991;20:690–7. 10.1093/ije/20.3.690 - DOI - PubMed
    1. Leon AS, Myers MJ, Connett J. Leisure time physical activity and the 16-year risks of mortality from coronary heart disease and all-causes in the Multiple Risk Factor Intervention Trial (MRFIT). Int J Sports Med 1997;18(Suppl 3):S208–15. 10.1055/s-2007-972717 - DOI - PubMed
    1. The multiple risk factor intervention trial (MRFIT). A national study of primary prevention of coronary heart disease. JAMA 1976;235:825–7. - PubMed

LinkOut - more resources

Feedback